Literature DB >> 6219611

Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain.

S Sorbi, E D Bird, J P Blass.   

Abstract

The activity of the pyruvate dehydrogenase complex (PDHC) was reduced in affected areas of brain from patients with Huntington disease (caudate, putamen) and Alzheimer disease (frontal cortex) where choline acetyltransferase (CAT) activity was low. PDHC was also deficient in an area (Huntington hippocampus) where CAT was not significantly reduced. The activity of fumarase, an inner mitochondrial marker, was normal in all areas examined. The activities of PDHC and CAT correlated well in caudate, putamen, and amygdala but not in hippocampus or frontal cortex. Both total activity and activation of PDHC were below normal in fibroblasts from 4 patients with C-21 trisomy Down syndrome, who are at very high risk to develop Alzheimer disease. However, no abnormality of PDHC was detected in Huntington or Alzheimer fibroblasts. Deficiency of PDHC may play a role in the pathophysiology of Huntington and Alzheimer diseases, although it does not appear to be a primary defect. Loss of tissue oxidative capacity may relate to the reduction in cerebral metabolic rate and blood flow which are characteristic of many dementing illnesses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6219611     DOI: 10.1002/ana.410130116

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  96 in total

Review 1.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

2.  Acetyl-L-carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury.

Authors:  Samir P Patel; Patrick G Sullivan; Travis S Lyttle; Alexander G Rabchevsky
Journal:  J Neurochem       Date:  2010-04-23       Impact factor: 5.372

Review 3.  The Alzheimer's disease mitochondrial cascade hypothesis.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 4.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

Review 5.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

6.  Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Authors:  S Hoyer; K Oesterreich; O Wagner
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

7.  Mitochondrial bioenergetics is defective in presymptomatic Tg2576 AD mice.

Authors:  Merina Varghese; Wei Zhao; Jun Wang; Alice Cheng; Xianjuan Qian; Amna Chaudhry; Lap Ho; Giulio Maria Pasinetti
Journal:  Transl Neurosci       Date:  2011-03-01       Impact factor: 1.757

8.  Negative Conditioning of Mitochondrial Dysfunction in Age-related Neurodegenerative Diseases.

Authors:  Sharmelee Selvaraji; Luting Poh; Venkateswaran Natarajan; Karthik Mallilankaraman; Thiruma V Arumugam
Journal:  Cond Med       Date:  2019-02

9.  Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.

Authors:  Yue-E Shen; Yan Wang; Gui-Chun Yu; Chao Liu; Zhen-Yu Zhang; Li-Ming Zhang
Journal:  Neurotox Res       Date:  2013-01-17       Impact factor: 3.911

Review 10.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.